Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | PDE5A | O76074 | 1/20 | 0.43 |
| ▸ | PDE1A | P54750 | 1/20 | 0.43 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.43 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | BRAF | P15056 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 2/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26622156 | 0.84 | LMNA (0.54) | MAPK1LMNAMAPTTSHRHTT | |
| SCHEMBL879988 | 0.84 | CYP1A2 (0.63) | MAPK1LMNAMAPTTSHRHTT | |
| SCHEMBL29508729 | 0.84 | CYP1A2 (0.63) | MAPK1LMNAMAPTTSHRHTT | |
| SCHEMBL10348307 | 0.84 | LMNA (0.50) | MAPK1LMNAMAPTTSHRHTT | |
| SCHEMBL513796 | 0.82 | LMNA (0.49) | MAPK1LMNAMAPTTSHRHTT | |
| SCHEMBL2787937 | 0.82 | TSHR (0.53) | MAPK1LMNAMAPTTSHRHTT | |
| SCHEMBL1448525 | 0.82 | TSHR (0.49) | MAPK1LMNAMAPTTSHRHTT | |
| SCHEMBL17714287 | 0.81 | LOXL2 (0.47) | MAPK1LMNAMAPTTSHRHTT | |
| SCHEMBL11547697 | 0.81 | MAPT (0.46) | MAPK1LMNAMAPTTSHRHTT | |
| SCHEMBL17812981 | 0.81 | LMNA (0.46) | MAPK1LMNAMAPTTSHRHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2278965-B1 | SUBSTITUTED PYRAZOLAMIDES AND THE USE THEREOF | AICURIS GMBH & CO KG (DE) | 2013-11-13 | — | — | EP | disclosed |
| EP-2176223-B1 | MALONAMIDE DERIVATIVES WITH ANTITHROMBOTIC ACTIVITY | SANOFI SA (FR) | 2013-01-23 | — | — | EP | disclosed |
| US-8314089-B2 | Substituted pyrazolamides and their use | AICURIS GMBH & CO. KG (DE) | 2012-11-20 | — | — | US | disclosed |
| US-8143242-B2 | Malonamide derivatives with antithrombotic activity | SANOFI-AVENTIS (FR) | 2012-03-27 | — | — | US | disclosed |
| US-20110172207-A1 | SUBSTITUTED PYRAZOLAMIDES AND THEIR USE | AICURIS GMBH & CO. KG (DE) | 2011-07-14 | — | — | US | disclosed |
| EP-2278965-A2 | SUBSTITUTED PYRAZOLAMIDES AND THE USE THEREOF | AiCuris GmbH & Co. KG (DE) | 2011-02-02 | — | — | EP | disclosed |
| US-20100249101-A1 | MALONAMIDE DERIVATIVES WITH ANTITHROMBOTIC ACTIVITY | SANOFI-AVENTIS (FR) | 2010-09-30 | — | — | US | disclosed |
| EP-2176223-A1 | MALONAMIDE DERIVATIVES WITH ANTITHROMBOTIC ACTIVITY | Sanofi-Aventis (FR) | 2010-04-21 | — | — | EP | disclosed |
| WO-2009115252-A2 | SUBSTITUTED PYRAZOLAMIDES AND THE USE THEREOF | AICURIS GMBH & CO. KG (DE) | 2009-09-24 | — | — | WO | disclosed |
| WO-2009007015-A1 | MALONAMIDE DERIVATIVES WITH ANTITHROMBOTIC ACTIVITY | SANOFI-AVENTIS (FR) | 2009-01-15 | — | — | WO | disclosed |
| US-6969716-B2 | 5-phenyl[1,2,4]triazines as ligands for GABA-A α2/α3 receptors for treating anxiety or depression | MERCK SHARP & DOHME LTD. | 2005-11-29 | — | — | US | disclosed |
| US-20040192692-A1 | 5-Phenyl[1,2,4]triazines as ligands for GABA-A alpha2/alpha3 receptors for treating anxiety or depression | MERCK SHARP & DOHME, LTD. (GB) | 2004-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249101-A1 | MALONAMIDE DERIVATIVES WITH ANTITHROMBOTIC ACTIVITY | F7, F9, TFPI | MAPK1 779/4885LMNA 546/4885MAPT 4829/4885 |
| US-20110172207-A1 | SUBSTITUTED PYRAZOLAMIDES AND THEIR USE | CACNA1A, P2RX4, KCNH1 | MAPK1 3105/4885LMNA 2155/4885MAPT 2703/4885 |
| US-20040192692-A1 | 5-Phenyl[1,2,4]triazines as ligands for GABA-A alpha2/alpha3 receptors for treating anxiety or depression | GABRA1, GABRA5, GABRA2 | MAPK1 1593/4885LMNA 2323/4885MAPT 3135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.